|
Dexcom G7 15-Day CGM Wins FDA Clearance
|
Written by: J. Smith |
Hits: 1421
|
|
Rybelsus® Cuts Cardiovascular Risk by 14% in SOUL Trial
|
Written by: J. Smith |
Hits: 1021
|
|
Ozempic® Shows New Benefit for People with Type 2 Diabetes and PAD
|
Written by: J. Smith |
Hits: 1312
|
|
Novo Nordisk Strikes $2 Billion Deal for Potential Rival to Lilly’s Triple Agonist Drug
|
Written by: J. Smith |
Hits: 998
|
|
Novo Nordisk Expands $499 Wegovy® Offer to Retail Pharmacies
|
Written by: J. Smith |
Hits: 669
|
|
Dexcom Receives FDA Warning Letter Over Manufacturing Issues
|
Written by: J. Smith |
Hits: 1330
|
|
Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations in REDEFINE 2 Trial
|
Written by: J. Smith |
Hits: 1109
|
|
Novo Nordisk Launches $499 Cash Program for Wegovy, Matching Eli Lilly’s Zepbound Pricing
|
Written by: J. Smith |
Hits: 833
|
|
Lilly Prepares for High Demand With $550M Stockpile of Oral GLP-1
|
Written by: J. Smith |
Hits: 742
|
|
Dexcom G7 Supply Disruptions
|
Written by: J. Smith |
Hits: 1686
|
